Stichting Hemato-Oncologie voor Volwassenen Nederland

• NCT06220032

  Phase 3, Recruiting, 324 people, 23 Jan 2024

• NCT06187441

  Phase 3, Recruiting, 599 people, 2 Jan 2024

• NCT06014489

  Phase 2, Recruiting, 142 people, 28 Aug 2023

• Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

  Phase 1/2, Recruiting, 112 people, 30 Mar 2023

• NCT05502250

  Phase 2, Active, not recruiting, 75 people, 16 Aug 2022

• NCT04639362

  Phase 2, Active, not recruiting, 85 people, 20 Nov 2020

• Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  Collaborator, Phase 3, Recruiting, 650 people, 13 Nov 2020

• NCT04608318

  Collaborator, Phase 3, Active, not recruiting, 897 people, 29 Oct 2020

• NCT04523428

  Phase 2, Recruiting, 60 people, 21 Aug 2020

• NCT04097470

  Phase 2, Active, not recruiting, 140 people, 20 Sept 2019

• NCT03868722

  Collaborator, Phase 2/3, Recruiting, 212 people, 11 Mar 2019

• NCT03673826

  Phase 2, Active, not recruiting, 58 people, 17 Sept 2018

• NCT03226301

  Phase 2, Status unknown, 230 people, 21 Jul 2017

• NCT03013998

  Collaborator, Phase 2/3, Recruiting, 3,000 people, 9 Jan 2017

• NCT02950051

  Collaborator, Phase 3, Completed, 926 people, 31 Oct 2016

• NCT01208766

  Phase 3, Completed, 1,503 people, 24 Sept 2010

• NCT00003152

  Collaborator, Phase 3, Terminated, 469 people, 2 Aug 2004

• NCT00004179

  Collaborator, Phase 3, Completed, 475 people, 27 Jan 2003

Sources: clinicaltrials.gov